Proacta Inc., an oncology drug discovery company focusing on novel therapies for hypoxic, or oxygen-starved, tumors, has raised NZ$12.5 million ($8.2 million) in its Series A round of venture capital.
Proacta Inc., an oncology drug discovery company focusing on novel therapies for hypoxic, or oxygen-starved, tumors, has raised NZ$12.5 million ($8.2 million) in its Series A round of venture capital.
